TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer

TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT05646511 by National Cancer Center Hospital East, with a registry enrolment figure of 608 participants, started 2022-11-21 and due to reach its primary completion in 2029-12-31. Interventions recorded: SCRT; CAPOX; CAPOXIRI. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Organ-preservation adapted DFS. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: Japan. No results are recorded here; the registry entry is the source.